• Molecular NameLubiprostone
  • Synonymlubiprostone; RU-0211
  • Weight390.467
  • Drugbank_IDDB01046
  • ACS_NO136790-76-6
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)4.08
  • pkaN/A
  • LogD (pH=7, predicted)1.97
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.17
  • LogSw (predicted, AB/LogsW2.0)0.05
  • Sw (mg/ml) (predicted, ACD/Labs)0.19
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds11
  • TPSA83.83
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA medication used in the management of idiopathic chronic constipation.
  • Absorption_valueN/A
  • Absorption (description)Lubiprostone has low systemic availability following oral administration and concentrations of lubiprostone in plasma are below the level of quantitation (10 pg/mL).
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding94.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmExtensive, CYP not involved
  • Half lifeUnknown (lubiprostone) 0.9~1.4 hours (main metabolite)
  • ExcretionRenal (60%) and fecal (30%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A